Facebook
Twitter
LinkedIn

FAST Company

Catena Biosciences

Current approaches for autoimmune therapies rely on symptom mitigation and inflammation reduction and require chronic medication for the patient’s lifetime. What is sorely needed is a disease modifying approach that targets the upstream cause of autoinflammation,┬áthe production of self-targeted antibodies. Catena’s platform allows for the rapid coupling of proteins for the creation of novel therapeutics for cancer, vaccines, and autoimmune disorders. Our mission is to advance our best-in-class protein coupling technology to create novel biotherapeutic cures for autoimmune disorders through selective tolerance induction.